Objectives: The aim of this this specialist work was to analyze medicinal products on the Croatian market / European Union that cause adverse reactions of respiratory system and classify them within defined limits of the frequency by using HALMED medicinal product base. This work gives an overview of medicinal products approved in Croatia / EU which cause adverse reactions specific respiratory system, classified within defined limits of the frequency. Material and methods: As materials for the preparation of this work several relevant scientific articles were used, that provides an overview so far recorded and describe respiratory adverse reactions and ways for their detection. Analysis of medicinal products that can cause adverse reactions specific respiratory system approved in Croatia / EU has been conducted: - Searching the internet site http://www.pneumotox.com/news/view/21/ (web site that is updated on a daily basis and on which can be find available list of medicinal products that have been reported to cause adverse reactions of specific respiratory system); - Searching HALMED medicinal product base; - The use of the register of medicinal product in Croatia for 2016. Results: In the tables were used Croatian names of active substances. The tables are structured in a way that medicines are in HALMED medicinal product base. If the drug is approved by the HALMED any dose or form is separetaly shown; if the drug is approved by the EMA all doses and forms are located within the same cell. A total of 4873 medicinal product were analysed (group A 422 medicinal product, group B 297 medicinal product, group C 784 medicinal product, group D 149 medicinal product, group G 219 medicinal product, group H 93 medicinal product, J group 626 medicinal product, group L 541 medicinal product, group M 234 medicinal product, group N 1039 medicinal product, group P 1 medicinal product, group R 344 medicinal product, group 74 medicinal product and group V 50 medicinal product). Conclusion: A total of 4873 medicinal product were analysed. Number of medicinal products with very common incidence of respiratory adverse reactions is 284, with common incidence of respiratory adverse reactions is 1435, with uncommon incidence of respiratory adverse reactions is 1573, with a rare incidence of respiratory adverse reactions is 881, with a very rare incidence of respiratory adverse reactions is 562, with not known frequency of respiratory adverse reactions is 972. Most common respiratory adverse reactions in all six categories of the incidence of adverse reactions were: dyspnoea, cough, epistaxis and rhinitis. Within all groups anatomical therapeutic classification of drugs, respiratory adverse reactions were described. The most very common respiratory adverse reactions were in a group L - Cytostatics (162 respiratory adverse reaction). The most common respiratory adverse reactions were in a group N - Nervous System (373 respiratory adverse reaction). The most uncommon respiratory adverse reactions were in the group C - Cardiovascular system (449 respiratory adverse reaction). The most rare respiratory adverse reactions were in the group N - Nervous System (251 respiratory adverse reaction). Most very rare respiratory adverse reactions were in the group C - Cardiovascular system (205 respiratory adverse reaction). Most of not known respiratory adverse reactions were in the group C - Cardiovascular system (270 respiratory adverse reaction).